MODERNA INC. DL-,0001 WKN: A2N9D9 ISIN: US60770K1079 Forum: Aktien Thema: Hauptdiskussion

Heute geht der Kurs über 190€🧗‍♀️

welche Shorts habt ihr?

Genau, Shorts kaufen 🙄

Dann bist aber spät rein. War unter 40 Euro zu haben. Hättest gutes Geld machen können

Mann o mann hätte ich diese Pommesbude doch nie gekauft

Ich befürchte auch, dass es weiter runter geht

Oh Mann, das wird heute weh tun🙈

Geht weiter runter

Perfetto 👍 du hast es sehr gut gelernt seit du bei BionTech warst. Hoffe es geht dir seitdem besser 😉

Mit Verlust verkaufen war keine Option für mich . Habe am Dienstag verkauft und meinen Einsatz mehr als verdoppelt.

Ich kann erstmal keine Positiven Nachrichten herauslesen , also war die Korrektur berechtigt…..Schauen wir mal was am Montag passiert 👻

'William Blair analyst Myles Minter questioned whether the stock declines were the result of a “sell-the-news reaction” or broader concern that there were no major differences in efficacy for patients with different mutational burdens in their tumors. Melanoma has a high mutational burden, which means immunotherapies work well against this kind of cancer. But much of the hope around the vaccine is that it will work in cancers with lower mutational burdens. “That alone is a reason to wait for the ESMO data presentation this weekend,” he told investors. The study enrolled about 1,100 patients with later-stage melanoma who first underwent surgery before receiving either intismeran and Keytruda or Keytruda alone. One of the key data points is the hazard ratio, an important measure that shows how long patients live before the cancer comes back. In the Phase 3 study, the hazard ratio was 0.58, which is on par or slightly lower than what Wall Street analysts had expected. It’s also similar to the hazard ratio in the smaller Phase 2 trial. A hazard ratio between 0.5 and 0.6 would be “a pretty good result,” RBC Capital Markets analyst Trung Huynh said Wednesday. That sentiment was echoed by BMO Capital Markets analyst Evan David Seigerman, who told investors that the “relative reduction in recurrence/death is clinically meaningful” even though it appears to have disappointed investors. Another important figure for investors is overall survival. Moderna and Merck said that data was not yet mature; however, they noted that there is a “favorable trend.” They are continuing the Phase 3 study to see how the data for overall survival turns out. ' https://www.gurufocus.com/news/9137576/leaked-neoantigen-therapy-data-sends-moderna-mrna-shares-tumbling-24?utm_source=marketwatch&utm_medium=syndication&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news

Leaked Neoantigen Therapy Data Sends Moderna (MRNA) Shares Tumbling 24% GuruFocus News 10/22/2026 21:26 + GuruFocus.com On October 22, 2026, leaked Phase III data on a neoantigen therapy linked to Moderna Inc (NASDAQ: MRNA) triggered a sharp 24% drop in the stock price amid mixed clinical signals and tempered market expectations. What's Behind the News? The recent leak of Phase III trial data for Moderna’s neoantigen therapy has stirred investor attention. Although the data was described as “unsubstantiated,” it reportedly demonstrated promising results consistent with expert expectations in oncology. The trial’s hazard ratio of 0.62 for distant metastasis-free survival, while positive, fell short of the higher benchmarks anticipated by some analysts. TD Cowen’s Tyler Van Buren noted that if these results are confirmed in the forthcoming official presentation, the therapy could become widely adopted, especially improving adjuvant treatment options for Stage II cancer patients.

Alle rein

Geht wieder hoch

https://www.deraktionaer.de/artikel/aktien/breaking-moderna-aktie-stuerzt-ab-stoppkurs-beachten-20423028.html